In addition to the CHOP-dependent pathway, CHOP-independent DR5 upregulation has been observed in certain cancer cells treated with TRAIL and other chemicals, such as Orlistat (XenicalTM) [44] and curcumin [45], although the key mediators of DR5 upregulation have not been identified. This evidence concerns the gene DDIT3 and cancer.